ClinicalTrials.gg
RecruitingNCT06381739AeroVaxUpdated Jan 26, 2026

A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol

A Phase 2 interventional study of ChAd-triCoV/Mac and Control in COVID-19 Infection, sponsored by McMaster University. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by McMaster University · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in COVID-19 by McMaster University — 1 open to participants now, 1 under way, none of them phase 3. COVID-19 · McMaster University.

Started
2025
the only one that year
Phase 2
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in COVID-19 by McMaster University, this one is the only one that started in 2025, is the only one in phase 2, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 15 studies in COVID-19 by McMaster University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in COVID-19 by McMaster University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).

To be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs.

During follow-up participants will:

  • visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination
  • report their symptoms for 24 weeks after getting the vaccine.

In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy).

Read the detailed description

The global impact of the coronavirus disease 2019 (COVID-19) pandemic remains profound; COVID-19 continues to be one of the leading causes of death and hospitalization due to infectious disease, disproportionately affecting the elderly and immunocompromised. The continuous evolution of the virus has significantly challenged the effectiveness of first-generation and updated vaccination strategies. These variants of concern (VOCs) can evade neutralizing antibodies.

Adequate and early lung mucosal immunity is critical for control of infection but current vaccines fail to induce robust mucosal immunity in the lungs, a major reason for the high rates of break-through infections. The respiratory mucosal route of immunization, however, can induce protective respiratory mucosal immunity consisting of trained innate immunity (via memory airway macrophages), mucosal antibodies, and tissue-resident memory CD4+/CD8+ T cells.

A phase 1 study has been completed using a recombinant chimpanzee adenovirus (ChAd) vector, ChAd-CoV3/Mac in 23 healthy volunteers and has shown that the vaccine can be safely administered by aerosol and that immune responses against COVID-19 develop in the lung and T-cells and neutralizing antibodies are generated in the blood.

The purpose of this placebo-controlled Phase 2 trial is to determine if this new COVID-19 vaccine, ChAd-triCoV/Mac, is safe to give by aerosol to people who have been vaccinated with at least three doses of a COVID mRNA vaccine and evaluate the immune responses generated. Specifically, the researchers want to see if T cell responses and antibody responses to the COVID virus proteins develop in the blood after receiving the vaccine.

There is a lack of surrogate immune markers for vaccine-induced protection against antibody-evading VOCs of SARS-CoV-2. However, given the now recognized importance of respiratory mucosal T cell immunity in anti-SARS-CoV-2 host defense, this study will allow for a correlation of mucosal T cell immunity with the T cells in blood to help predict vaccine efficacy, and inform the design of phase 3 efficacy studies.

03

Conditions studied

  • COVID-19 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults who are 18-65 years old on the day of randomization (day 1)
  2. Able to read, write and communicate using the English or French language.
  3. Received at least 3 doses of an mRNA COVID vaccine.
  4. Individuals of must have a negative pregnancy test prior to vaccination and be willing to practice effective for 8 weeks post-vaccination.
  5. Able to understand and comply with protocol requirements and instructions; able to report adverse events; able to attend scheduled study visits and complete required investigations.
  6. For participants in the BAL sub-study, Complete Blood Count (CBC) and chemistry (creatinine) within normal limits.
  7. For participants in the BAL sub-study, (FEV1) > the lower limit of normal (LLN), and FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) ratio above the LLN.
  8. Agree not to enroll in any other intervention studies for the duration of the study where the intervention could be reasonably expected to be associated with adverse events overlapping with the inhaled vaccine or the immune responses being measured.

Exclusion criteria

Exclusion criteria:

  1. Failure to provide .
  2. Women who are pregnant or breastfeeding.
  3. Have received any recombinant adenoviral-vectored COVID-19 vaccine (AstraZeneca [Vaxzeria] or Johnson \& Johnson (Janssen Jcovden).
  4. COVID infection (positive PCR or antigen (Ag) test, self-reported or lab documented) within the last 90 days.
  5. Last dose of a COVID vaccine administered less than 90 days prior to study entry.
  6. Administration of any vaccine within 2 weeks of study entry.
  7. Active pulmonary disease diagnosed by a physician including asthma, chronic bronchitis, interstitial lung disease, pulmonary hypertension, lung cancer, cystic fibrosis, or bronchiectasis. Current use of daily inhaled for any condition.
  8. Persons with and a detectable HIV viral load (>20 copies/mL), self-reported or confirmed.
  9. Administration of monoclonal antibodies for treatment of COVID-19 infection within 3 months.
  10. Moderately or severely (e.g. transplant recipients/CAR-T cell therapy, currently on chemotherapy for cancer or on potent immunosuppressant therapies e.g. rituximab or high dose steroids [>30 mg of prednisone equivalent daily], or moderate or severe primary immunodeficiency syndrome).
  11. History of severe reaction to previous COVID vaccination (e.g. hives, difficulty breathing, high fever, seizures, myocarditis, pericarditis)).
  12. Potential to COVID vaccination (e.g. venous or arterial thrombosis with thrombocytopenia after vaccination, history of cerebral venous thrombosis with thrombocytopenia, history of heparin induced thrombocytopenia, history of myocarditis or pericarditis).
  13. Known allergy to vaccine components or previous receipt of any experimental adenovirus-vector vaccine by the aerosol route.
  14. Enrolment in any clinical trial of experimental treatment for COVID infection within 90 days.
  15. For participants in the BAL sub-study, any health-related condition for which study bronchoscopy is contraindicated.
  16. For participants in the BAL sub-study, current use of anticoagulants.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    ChAd-triCoV/Mac

    ChAd-triCoV/Mac

    Biological: ChAd-triCoV/Mac

  • Placebo comparator
    Control

    Placebo

    Other: Control

Interventions

  • BiologicalChAd-triCoV/Mac

    Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.

  • OtherControl

    A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.

06

What researchers measure

Primary outcomes

  1. Antigen specific T cell responses in blood.

    Percentage of cytokine positive T cells in the blood

    Time frame: 2 weeks

  2. Antigen specific T cell responses in bronchoalveolar lavage (BAL).

    Percentage of cytokine positive T cells in the BAL

    Time frame: 4 weeks

  3. Any grade 3, 4, or 5 adverse events that are possibly or probably related to study vaccine.

    Frequency, incidence and nature of adverse events

    Time frame: 24 weeks

Secondary outcomes

  1. Confirmed COVID infection by reverse transcriptase polymerase chain reaction (RT-PCR)

    Positive RT-PCR test

    Time frame: 24 weeks

  2. CD4 and CD8 T cell responses specific for the spike (S1), nucleoprotein (N) and polymerase (POL) SARS-CoV-2 antigens expressed by the vaccine, including those expressing memory T cell markers, in the peripheral blood.

    Percentage of cytokine positive T cells in the blood to specific antigens

    Time frame: 4 and 8 weeks

  3. Neutralizing and total antibody levels in BAL and blood

    Anti-receptor binding domain (RBD) IgG and IgA endpoint titre; percent neutralization (surrogate virus neutralization test \[sVNT\])

    Time frame: 2, 4 and 8 weeks

  4. Any adverse events, including grade 1 or 2 or where relationship to vaccine/placebo administration or study procedures is judged not related or unlikely.

    Frequency, incidence and nature of any adverse events

    Time frame: 24 weeks

  5. Tissue-resident memory surface marker expression airway T cells

    Percentage CD103+CD8+ specific cells

    Time frame: 4 weeks

07

Study locations

2 of 2 sites recruiting
  • Canadian Center for Vaccinology, Dalhousie University
    Halifax, Nova Scotia B3K 6R8, Canada
    Recruiting
    • Study Coordinator · Contact902-470-3742
    • Scott Halperin, MD · Principal investigator
  • Health Sciences Centre
    Hamilton, Ontario L8S 4K1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The full protocol and details of laboratory analyses will be published within 6 months of study enrolment. The statistical analysis plan and individual participant data will be made available to qualified researchers on request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 6 months following enrolment for protocol and statistical analysis plan. Individual participant data available following analysis.

Access criteria: Full protocol will be published; statistical analysis plan and individual participant data available on request from qualified researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 21 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 24, 2024
StartActual
Mar 25, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06381739
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Mar 25, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

Marilyn Swinton
Contact
swinton@mcmaster.ca
289-244-3997
Fiona Smaill
principal investigator · McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion